Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Diagnos Inc V.ADK

Alternate Symbol(s):  DGNOF

Diagnos Inc. is a Canadian company, which is engaged in early detection of critical health problems based on its FLAIRE artificial intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications, such as computer assisted retina analysis (CARA). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a tool for real-time screening of large volumes of patients. It provides software-based services to assist health specialists in the detection of diabetic retinopathy and other eye-related pathologies. Its geographical areas include Canada, the United States of America, Mexico, and Chile. The Company’s subsidiaries include Diagnos Internacional SA de CV and Diagnos Healthcare (India) Private Limited.


TSXV:ADK - Post by User

Bullboard Posts
Post by u2bobon Nov 18, 2017 11:14am
192 Views
Post# 26989233

Google vs ADK ...

Google vs ADK ...You can bet your last sweet dollar that Google knows about ADK...

Could Artificial Intelligence Revolutionize the Treatment of Eye Diseases?

September 5th, 2017 by Dr. Chad Andrews

 

Artificial intelligence is in the news more frequently than ever, but it’s not typically associated with vision research.

That may not be the case for long: incredible progress is being made in the application of artificial intelligence (AI) to the detection and prognosis of eye diseases such as age-related macular degeneration (AMD) and diabetic retinopathy.

In conditions such as AMD, damaged blood vessels at the back of the eye lead to vision loss of varying degrees. Diagnosing these diseases can be complicated, involving the close analysis of images of the retina.

Today, the human retina is routinely imaged with a variety of tools, such as optical coherence tomography (OCT) and fundus photography. Adaptive optics is another example: the exciting new technology enables the visualization of single photoreceptors, the eye’s light sensitive cells that are damaged in many blinding eye diseases.

Experts study these images in order to diagnose eye diseases and study their progression and response to treatments over time. This is where AI enters the picture.

Researchers at Stanford University are developing algorithms that are intelligent enough to differentiate a healthy eye from a damaged one. It’s a form of automated detection, an approach that could revolutionize retinal imagining and enable clinicians to pinpoint and treat eye diseases at earlier stages, before the retina is severely damaged.

Using software engineered from Google, the Stanford team trained computer models to get better at interpreting fundus photographs, showing that their model can successfully pick out an image of an eye damaged by diabetic retinopathy—the work was recently published in Ophthalmology. AI specialists refer to this as a form of “deep learning,” where machines are subjected to patterns of data—in this case, images of eyes—until the act of recognizing them becomes deeply ingrained.

In Canada, automated detection is being advanced by Dr. Choudhry, co-founder of the Vitreous Retina Macula (VRM) Specialists of Toronto clinic. He and his team are at the cutting-edge of deep learning applications, and are hard at work developing their own detection software. To hear more about Dr. Choudhry’s work, you can register for the September 19 Vision Quest event at the Toronto Reference Library, where he will discuss innovative vision treatments and the future of AMD.

With projects similar to Dr. Choudhry’s and the work at Stanford progressing across the globe, we could very well be approaching a new frontier in retinal imaging, and a better future for those living with retinal diseases.

Sources Cited:

Gargeya, Rishab & Leng, Theodore (2017). “Automated Identification of Diabetic Retinopathy Using Deep Learning.” Ophthalmology, 7, 962-969.

Bullboard Posts